Adult embryonal tumor with multilayered rosettes, c19mc-altered
disease diseaseOn this page
Also known as adult embryonal tumour with multilayered rosettes, C19MC-alteredadult ependymoblastomaembryonal tumor with multilayered rosettes, C19MC-alteredembryonal tumour with multilayered rosettes, C19MC-alteredependymoblastoma of adults
Summary
Adult embryonal tumor with multilayered rosettes, c19mc-altered (MONDO:0004310) is a cancer and 9 clinical trials. Top therapeutic interventions include plerixafor, carboplatin, and edotreotide gallium ga-68. A subtype of adult central nervous system primitive neuroectodermal neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 9
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | adult embryonal tumor with multilayered rosettes, c19mc-altered |
| Mondo ID | MONDO:0004310 |
| DOID | DOID:7631 |
| NCIT | C8290 |
| UMLS | C0281330 |
| MedGen | 83792 |
| GARD | 0023925 |
| Is cancer (heuristic) | yes |
Also known as: adult embryonal tumor with multilayered rosettes, C19MC-altered · adult embryonal tumour with multilayered rosettes, C19MC-altered · adult ependymoblastoma · embryonal tumor with multilayered rosettes, C19MC-altered · embryonal tumour with multilayered rosettes, C19MC-altered · ependymoblastoma of adults
Disease family
This is a subtype of adult central nervous system primitive neuroectodermal neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › central nervous system primitive neuroectodermal neoplasm › adult central nervous system primitive neuroectodermal neoplasm › adult embryonal tumor with multilayered rosettes, c19mc-altered
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 9.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 3 |
| PHASE1 | 3 |
| Not specified | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00983398 | PHASE1/PHASE2 | UNKNOWN | Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors |
| NCT01977677 | PHASE1/PHASE2 | COMPLETED | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma |
| NCT02095132 | PHASE1/PHASE2 | COMPLETED | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
| NCT00030498 | PHASE1 | COMPLETED | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction |
| NCT00110032 | PHASE1 | TERMINATED | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors |
| NCT01119599 | PHASE1 | COMPLETED | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma |
| NCT01234805 | Not specified | TERMINATED | Yoga Therapy in Treating Patients With Malignant Brain Tumors |
| NCT02194452 | Not specified | WITHDRAWN | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors |
| NCT02967380 | Not specified | TERMINATED | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PLERIXAFOR | 4 | 2 |
| CARBOPLATIN | 4 | 1 |
| EDOTREOTIDE GALLIUM GA-68 | 4 | 1 |
| GADOBENATE DIMEGLUMINE | 4 | 1 |
| GADOBUTROL | 4 | 1 |
| GADOPENTETATE DIMEGLUMINE | 4 | 1 |
| MANNITOL | 4 | 1 |
| SODIUM THIOSULFATE | 4 | 1 |
| SORBITOL | 4 | 1 |
| ADAVOSERTIB | 2 | 1 |
| CHEMBL3753202 | 0 | 1 |